Blog
RSS FeedPosted by Michael Wonder on 02 Oct 2018
A payer’s perspective on value-based contracting
1 October 2018 - What payer wouldn’t want to ensure that they pay for value when buying drugs? If the ...
Posted by Michael Wonder on 27 Sep 2018
With payers under pressure, biosimilars must demonstrate their value
27 September 2018 - In recent years, payers in Europe have been increasing their scrutiny of new therapies as increasingly high-cost ...
Posted by Michael Wonder on 27 Sep 2018
Paying for value: US state of play
27 September 2018 - Drug pricing in the US is a perennial topic, which is no surprise given the the ...
Posted by Michael Wonder on 19 Sep 2018
Payment and delivery system reform — the next phase
19 September 2018 - After nearly a decade of experimentation with value-based payment, U.S. health care payers, providers, and purchasers are ...
Posted by Michael Wonder on 15 Sep 2018
Patient groups attack CVS use of ICER metrics, urge rethink
14 September 2018 - More than 90 organisations, predominantly patient groups, criticised CVS Caremark's decision last month to incorporate value-based drug ...
Posted by Michael Wonder on 07 Sep 2018
Is US medical care inefficient?
7 September 2018 - Is US medical care inefficient? Many health policy experts maintain it is, whereas others prefer a ...
Posted by Michael Wonder on 05 Sep 2018
Publication of final base-case ICERs (ICURs) by health technology assessment agencies
6 September 2018 - The Department of Health is dragging its heels on this issue. ...
Posted by Michael Wonder on 04 Sep 2018
Why aren't final base-case ICERs published in the PBAC Public Summary Documents?
5 September 2018 - The case for not doing so is now very weak. ...
Posted by Michael Wonder on 04 Sep 2018
Medicaid to introduce value-based drug pricing
4 September 2018 - States have often been an incubator for innovative ideas in health technology pricing and reimbursement. ...
Posted by Michael Wonder on 03 Sep 2018
Medicare-funded cancer genetic tests: a note of caution
3 September 2018 - Clinicians need appropriate education and support in keeping pace with the genomics revolution. ...
Posted by Michael Wonder on 16 Aug 2018
US insurers can peg access to ICER value reviews
16 August 2018 - Latest step in US pricing evolution. ...
Posted by Michael Wonder on 13 Aug 2018
CVS' move to lean on ICER data could mean dramatic shift in drug pricing leverage
13 August 2018 - In an ongoing war over drug prices, leading pharmacy benefit manager CVS Caremark is rolling out ...
Posted by Michael Wonder on 10 Aug 2018
Biosimilars for insulin: a cost-saving alternative?
11 August 2018 - The expiry of patents on an insulin analogue has opened the market to the production of biosimilar ...
Posted by Michael Wonder on 09 Aug 2018
Too-keen medicos cost patients millions
8 August 2018 - Medical procedures likely to have little clinical benefit are still being performed in Australian hospitals, wasting ...
Posted by Michael Wonder on 08 Aug 2018
Comparing the ICERs in medicine reimbursement submissions to NICE and PBAC—does the presence of an explicit threshold affect the ICER proposed?
8 August 2018 - The English NICE and the Australian PBAC require evidence that a new medicine represents value for money ...